Eli Lilly recently won its third straight trial over the withdrawal risks of its antidepressant Cymbalta, persuading a federal jury that warnings on the drug were adequate. Defense attorneys say this key finding gives the drugmaker an edge in an upcoming fight with plaintiffs trying to consolidate dozens of similar suits.
Litigation partner William Hoffman weighed in on Lilly's recent successes for Law360:
"From my perspective watching this litigation, this company has a strong defense that's being well-presented, that there is strong labeling for this product and that it's giving them the upper hand with judges considering summary judgment motions and at trial. That's going to weigh heavily on the JPML panel, since it has already rejected an earlier consolidation petition."
Also of Interest
- And Now A Word From The Panel: 3 Alternatives To MDLs September 28, 2016 • Articles
- Kaye Scholer Represents Investors in Volkswagen Diesel Emissions Litigation September 28, 2016 • Client Successes
- NLJ Names Shores as Antitrust Trailblazer September 27, 2016 • Recognitions
- Shape of Things to Come: Protecting Product Configuration and Packaging Design September 26, 2016 • Articles
- On the Road to a Safe and Secure Internet of Things: What Companies Should Do September 19, 2016 • Articles
- Druckenbrodt Quoted in Bloomberg on Volkswagen Dieselgate September 14, 2016 • Media Mentions
- Arbisser Featured in The Recorder and Law360... September 7, 2016 • Media Mentions
- Consumer Products: Adapting to Innovation Fall 2016 • Reports / Newsletters
- ILS and Zinsser Analytic Shareholders Sell to Gardner Denver Medical September 2, 2016 • Client Successes